We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-5.96%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$256M
AUM Growth
+$1.99M
(+0.78%)
Cap. Flow
+$21M
Cap. Flow
% of AUM
8.19%
Top 10 Holdings %
Top 10 Hldgs %
54.27%
Holding
61
New
20
Increased
9
Reduced
8
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$19M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.6M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.9M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$12.8M |
| 5 |
Celldex Therapeutics
CLDX
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$24.4M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15M |
| 3 |
United Therapeutics
UTHR
|
+$9.92M |
| 4 |
Eli Lilly
LLY
|
+$9.5M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$9.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.85% |
| 2 | Consumer Staples | 3.25% |
| 3 | Financials | 0.9% |
| 4 | Real Estate | 0.04% |
| 5 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$15.5B
| $20.3M | 7.95% |
+130,678
| New | +$19M |
|
|
2
Protagonist Therapeutics
PTGX
$9.06B
| $18.2M | 7.12% |
769,250
+455,321
| +145% | +$12.8M |
|
|
3
Regeneron Pharmaceuticals
REGN
$70.9B
| $15M | 5.86% |
+21,477
| New | +$13.6M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $13.9M | 5.44% |
+132,332
| New | +$12.9M |
|
|
5
Celldex Therapeutics
CLDX
$2.77B
| $13.1M | 5.1% |
+383,319
| New | +$12.3M |
|
6
Edwards Lifesciences
EW
$49.4B
| $12.6M | 4.91% |
106,790
-40,606
| -28% | -$4.56M |
|
|
KZR
7
DELISTED
Kezar Life Sciences
KZR
| $12.1M | 4.75% |
73,090
-162
| -0.2% | -$23.3K |
|
|
8
Eli Lilly
LLY
$1.05T
| $11.9M | 4.65% |
41,610
-36,918
| -47% | -$9.5M |
|
9
argenx
ARGX
$53.8B
| $11.3M | 4.42% |
35,880
-12,467
| -26% | -$3.62M |
|
10
Adicet Bio
ACET
$75.9M
| $10.4M | 4.08% |
32,704
-3,759
| -10% | -$865K |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.06M | 3.54% |
406,733
+193,559
| +91% | +$4.94M |
|
12
Bristol-Myers Squibb
BMY
$124B
| $8.97M | 3.5% |
+122,817
| New | +$8.25M |
|
|
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.49M | 3.32% |
+504,371
| New | +$7.45M |
|
14
Stevanato
STVN
$5.23B
| $8.39M | 3.28% |
416,920
+190,220
| +84% | +$3.32M |
|
15
SkinHealth Systems
SKIN
$109M
| $8.33M | 3.25% |
493,301
-12,979
| -3% | -$214K |
|
16
Evolent Health
EVH
$654M
| $7.48M | 2.92% |
231,499
+6,402
| +3% | +$168K |
|
17
Exelixis
EXEL
$14.1B
| $7.46M | 2.91% |
+329,068
| New | +$6.43M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.43M | 2.9% |
296,327
-139,973
| -32% | -$3.93M |
|
19
Fate Therapeutics
FATE
$324M
| $7.38M | 2.88% |
190,345
+48,313
| +34% | +$1.87M |
|
|
BLU
20
DELISTED
BELLUS Health Inc.
BLU
| $6.95M | 2.71% |
1,009,615
+33,682
| +3% | +$217K |
|
21
Aldeyra Therapeutics
ALDX
$102M
| $6.43M | 2.51% |
+1,447,445
| New | +$5.77M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.14M | 2.4% |
51,750
+27,404
| +113% | +$3.42M |
|
|
RXDX
23
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $5.63M | 2.2% |
+149,066
| New | +$5.89M |
|
24
BioNTech
BNTX
$23.1B
| $5.27M | 2.06% |
+30,923
| New | +$5.2M |
|
25
Revolution Medicines
RVMD
$39.6B
| $4.35M | 1.7% |
+170,455
| New | +$3.71M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Tri Locum Partners held 61 positions worth $256M, up 0.78% from $254M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $21M of net new capital in Q1 2022, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $9.5M trimmed.
- Tri Locum Partners's largest Q1 2022 buy was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
- Tri Locum Partners added most to Protagonist Therapeutics in Q1 2022, an estimated $12.8M increase.
- Tri Locum Partners's biggest Q1 2022 reduction was Eli Lilly, cutting an estimated $9.5M.
- Tri Locum Partners fully exited AbbVie in Q1 2022, selling an estimated $24.4M.
- Tri Locum Partners's ten largest holdings make up 54% of its $256M portfolio in Q1 2022.
- Tri Locum Partners opened 20 new positions and closed 24 in Q1 2022.
- Tri Locum Partners's portfolio value rose 0.78% quarter-over-quarter to $256M.
Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.